Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1348-1356

  Atsumi, Tatsuya ^a   Tanaka, Yoshiya ^b   Yamamoto, Kazuhiko ^c   Takeuchi, Tsutomu ^d   Yamanaka, Hisashi ^e   Ishiguro, Naoki ^f   Eguchi, Katsumi ^g   Watanabe, Akira ^h   Origasa, Hideki ⁱ   Yasuda, Shinsuke ^a   Yamanishi, Yuji ^j   Kita, Yasuhiko ^k   Matsubara, Tsukasa ^l   Iwamoto, Masahiro ^m   Shoji, Toshiharu ⁿ   Togo, Osamu ⁿ   Okada, Toshiyuki ^o   Van Der Heijde, Désirée ^p   Miyasaka, Nobuyuki ^q   Koike, Takao ^a,r  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g SASEBO CHUO HOSPITAL   (Japan)

^h TOHOKU UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOYAMA   (Japan)

^j Department of Rheumatology   (Japan)

^k YOKOHAMA ROSAI HOSPITAL   (Japan)

^l Matsubara Mayflower Hospital   (Japan)

^m JICHI MEDICAL UNIVERSITY   (Japan)

ⁿ UCB PHARMA   (Belgium)

^o ASTELLAS PHARMA INC   (Japan)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^r NTT CORPORATION   (Japan)

more..

Author keywords

Anti TNF; DMARDs (biologic); Early Rheumatoid Arthritis; Methotrexate

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; INFECTION; INFESTATION; INFORMATION SCIENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHARP SCORE; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DEPRESCRIPTION; EARLY INTERVENTION; RETREATMENT; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; DEPRESCRIPTIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME;

EID: 85013404930     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210246     Document Type: Article

References (27)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Finckh A, Liang MH, van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 2006;55:864-72.
3. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
4. Atsumi T, Yamamoto K, Takeuchi T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 2016;75:75-83.
5. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
6. van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
7. Smolen JS, Landewá R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
8. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
9. Lukas C, van der Heijde D, Fatenajad S, et al. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis 2010;69:851-5.
10. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012;8:656-64.
11. Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 2015;1(Suppl 1):e000057.
12. van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med 2014;12:25.
13. Ochi T, Iwase R, Yonemasu K, et al. Natural course of joint destruction and fluctuation of serum C1q levels in patients with rheumatoid arthritis. Arthritis Rheum 1988;31:37-43.
14. Kyburz D, Gabay C, Michel BA, et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011;50:1106-10.
15. Raza K, Saber TP, Kvien TK, et al. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012;71:1921-3.
16. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276-89.
17. Hoff M, Kvien TK, Kälvesten J, et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord 2011;12:54.
18. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
19. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
20. Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005;162:1016-23.
21. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1-26.
22. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
23. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54: 26-37.
24. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
25. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
26. Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis 2014;73:536-43.
27. Takahashi C, Kaneko Y, Okano Y, et al. THU0118 Methotrexate Polyglutamates in Erythrocytes Correlates with Clinical Response in Japanese Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014;73(Suppl 2):218-19.